Navigation Links
Isis Reports Financial Results and Highlights for First Quarter 2013
Date:5/7/2013

ible to receive up to $362 million in a license fee, pre-licensing and post-licensing milestone payments, including up to $80 million in commercial milestones.
  • In addition, Isis is eligible to receive up to $136.5 million in milestone payments for each additional drug successfully developed plus up to $50 million in commercial milestones if a drug using Roche's proprietary brain shuttle technology is successfully commercialized.
  • Isis is also eligible to receive tiered royalties on sales of drugs arising from the alliance. 
  • Conference CallAt 4:30 p.m. Eastern Time today, May 7, 2013, Isis will conduct a live webcast conference call to discuss this earnings release and related activities.  Interested parties may listen to the call by dialing 1-866-652-5200 and provide the conference identification number "10028266", or access the webcast at www.isispharm.com.  A webcast replay will be available for a limited time at the same address.

    ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology. 

    FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis Pharmaceuticals' financial position and outlook, Isis' business, and the therapeutic and commercial potential of Isis' technologies and products in development.  Any statement d
    '/>"/>

    SOURCE Isis Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Perrigo Reports Record Revenue and Adjusted Earnings
    2. Discovery Labs Reports First Quarter 2013 Financial Results
    3. Endo Reports First Quarter Financial Results
    4. Landauer, Inc. Reports Fiscal 2013 Second Quarter Results
    5. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
    6. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
    7. IRIDEX Reports 2013 First Quarter Results
    8. Masimo Reports First Quarter 2013 Financial Results
    9. Neurocrine Biosciences Reports First Quarter 2013 Results
    10. Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2013 Financial Results
    11. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
    (Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
    (Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
    Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
    ... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
    ... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
    Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
    (Date:8/21/2014)... considered nearly eradicated. Each year only a few hundred ... of Bonn, together with colleagues from Gabon, are reporting ... resist the vaccine protection to a considerable extent was ... in 2010. The pathogen could also potentially have infected ... the magazine PNAS . , The polio epidemic ...
    (Date:8/21/2014)... Maryland (PRWEB) August 21, 2014 As ... the U.S. Pharmacopeial Convention (USP) has joined with the ... threat posed by the illegal online sale of medicines. ... benefits of medicines and foods is a core mission ... health around the world,” said Ronald T. Piervincenzi, chief ...
    (Date:8/21/2014)... It's a terrible thing when a young adult, ... substance abuse issue. When that happens to a teenager in ... reliable help from the qualified substance abuse therapists at a ... easy for those young adults living in Pompano Beach, FL ... , Thankfully there is a new helpline operating for ...
    (Date:8/21/2014)... CA (PRWEB) August 21, 2014 David ... is a short but powerful collection of quotes from ... uplift and inspire other budding entrepreneurs on their challenging ... proud to announce the inclusion of President and Founder ... from highly successful and self-made celebrities such as Oprah ...
    (Date:8/21/2014)... by T-type calcium channels in the thalamic reticular ... calcium. These channels enable thalamic reticular nucleus neurons ... enter a hyper-excited state. , In order to ... seizures, the researchers conducted an experiment to induce ... to delete the T-type calcium channel CaV3.3. The ...
    Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:USP Joins Efforts to Halt Illegal Online Drug Sales 2Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2
    ... , FRIDAY, July 29 (HealthDay News) -- Some ethnic groups are ... organs as they gain weight, according to a new study. ... artery disease, is more common among people from South Asia, the ... journal PLoS ONE . "The new study showed South ...
    ... may also be contributing to hearing loss. Scientists mapped ... The distinctive roar of a Harley,s engine is ... noise for motorcyclists is actually generated by air whooshing ... sound can exceed safe levels. Now, scientists have identified ...
    ... testing at local emergency departments shows that hospitals miss opportunities ... with HIV, even when a regular testing program is in ... to the July issue of Annals of Emergency Medicine ... (CDC). The supplement includes a series of studies on HIV ...
    ... When people recognize voices, part of what helps make ... differently. But individuals with dyslexia don,t experience this familiar ... impairment." Tyler Perrachione with the Massachusetts Institute of ... language use the same words, they say those words ...
    ... protect skin cells from the sun,s ultraviolet radiation, according ... Barcelona and the CSIC (Spanish National Research Council). The ... in sun protection products. Ultraviolet (UV) rays emitted ... skin complaints, causing skin cancer, sunburn and solar erythema, ...
    ... The U.S. Food and Drug Administration should gather the ... the 35-year-old 510(k) clearance process for medical devices, says a ... process lacks the legal basis to be a reliable premarket ... devices and cannot be transformed into one, concluded the committee ...
    Cached Medicine News:Health News:Some Ethnic Groups More Vulnerable to Dangerous Fat 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 2Health News:Study shows missed opportunities for HIV diagnosis in emergency departments 3Health News:Dissecting dyslexia: Linking reading to voice recognition 2Health News:Dissecting dyslexia: Linking reading to voice recognition 3Health News:Grapes protect against ultraviolet radiation 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 2Health News:FDA should invest in developing a new regulatory framework to replace flawed 510(k) medical device clearance process 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: